Item 8.01. Other Events.

On July 7, 2021, Vaxart, Inc. (the "Company") issued a press release announcing that it had entered into a license agreement with Altesa Biosciences, Inc. ("Altesa") on July 6, 2021, to allow Altesa to develop and commercialize the Company's patented formulation of the capsid-binding VapendavirTM, a clinical-stage broad spectrum antiviral. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On July 2, 2021, the board of directors of the Company appointed Todd C. Davis as the Chairman of the Board, effective as of July 1, 2021.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description



99.1              Press Release



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses